MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
19.67
+0.36
+1.86%
After Hours: 19.72 +0.05 +0.25% 19:39 04/10 EDT
OPEN
19.31
PREV CLOSE
19.31
HIGH
19.89
LOW
19.15
VOLUME
2.52M
TURNOVER
--
52 WEEK HIGH
36.91
52 WEEK LOW
13.83
MARKET CAP
15.25B
P/E (TTM)
-13.6228
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst
Benzinga · 3d ago
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Benzinga · 3d ago
SUMMIT THERAPEUTICS INC <SMMT.O>: STIFEL INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $45
Reuters · 3d ago
Summit Therapeutics Initiated at Buy by Stifel
Dow Jones · 3d ago
Summit Therapeutics Price Target Announced at $45.00/Share by Stifel
Dow Jones · 3d ago
Stifel Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $45
Benzinga · 3d ago
Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit
TipRanks · 4d ago
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.